CIK 0001404281
- Non-accelerated filer
- Smaller reporting company
Eledon Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 949-238-8090
- Business address
- 19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
- Former names
- Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
- 4 Open-market sale President sold 9,537 shares at an average $1.95 ($18,612)
- 4 Open-market sale See Remarks sold 5,276 shares at an average $1.95 ($10,296)
- 4 Open-market sale Chief Executive Officer sold 14,638 shares at an average $1.95 ($28,566)
- 4 Open-market buy Director bought 646,204 shares at $3.10 ($2,003,232)
- 4 Open-market buy Director bought 646,204 shares at $3.10 ($2,003,232)
- 4 Open-market sale 10% owner sold 200 shares at $2.70 ($540)
- 4 Grant or award President acquired 20,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 25,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President bought 33,680 shares at an average $4.78 ($161,147)
- 4 Open-market buy President bought 805 shares at $3.97 ($3,193)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award See Remarks acquired 11,250 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 30,700 shares (grant or award)
- 4 Grant or award President acquired 20,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 6 of 11 · 212 filings